Umpierrez G, et al. - Researchers analyzed the impact of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) on the relative contribution of basal hyperglycemia (BHG) and post-prandial hyperglycemia (PPHG) to overall hyperglycemia across HbA1c categories after six months of treatment intensification with dulaglutide 1.5 mg as monotherapy or with one or two oral drugs in type 2 diabetes patients. To measure the change in relative contributions of BHG and PPHG, they used data from five phase 3 studies (N=673). Investigators found that relative contributions of BHG increased and PPHG reduced with increasing HbA1c levels at baseline. Even as overall glycemia got better in every HbA1c category with decreasing values, this pattern was sustained at 6 months. According to findings, dulaglutide lowers HbA1c in patients with type 2 diabetes by lowering both basal and post-prandial hyperglycemia at different levels of HbA1c.